Eikon Therapeutics earnings were -$337.1M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest EIKN earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$86.1M, down 2.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, EIKN reported annual earnings of -$333.6M, with 36.8% growth.
What were Eikon Therapeutics's earnings last quarter?
On EIKN's earnings call on Nov 12, 2026, Eikon Therapeutics (NASDAQ: EIKN) reported Q3 2026 earnings per share (EPS) of -$1.59, up 93.44% year over year. Total EIKN earnings for the quarter were -$86.11 million. In the same quarter last year, Eikon Therapeutics's earnings per share (EPS) was -$24.24.
As of the last Eikon Therapeutics earnings report, Eikon Therapeutics is currently losing money. Eikon Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$337.13 million, a 8.92% increase year over year.
What was EIKN's earnings growth in the past year?
As of Eikon Therapeutics's earnings date in Nov 12, 2026, Eikon Therapeutics's earnings has grown year over year. EIKN earnings in the past year totalled -$337.13 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.